Low-dose Sargramostim Shows Promise in Small Early Trial
Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical trial of people with Parkinson’s disease. The results “provide the basis for larger scale assessments to determine clinical efficacy of a reduced sargramostim regimen within the [Parkinson’s] population,” according…